OREX 1038

Drug Profile

OREX 1038

Alternative Names: OREX-1038

Latest Information Update: 10 Jan 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator University of Bath
  • Developer Orexigen Therapeutics; University of Bath
  • Class Opioid analgesics
  • Mechanism of Action Opioid mu receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cocaine abuse; Opioid abuse

Most Recent Events

  • 05 Jan 2017 Orexigen Therapeutics announces intention to submit IND in 2018
  • 16 Nov 2016 Preclinical trials in Cocaine abuse in USA (unspecified route)
  • 16 Nov 2016 Preclinical trials in Opioid abuse in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top